Floatz logo

h3b-6545

Breast Adenocarcinoma

Eisai Inc.Phase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Breast Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3BB
TRASTUZUMAB
Academic and Community Cancer Research United
Phase 3BB
Inno-206
Virginia Commonwealth University
Phase 3BB
Letrozole
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BB
Carboplatin
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

h3b-6545 is also rated in:

breast neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
ER PositiveDormant
CCC
Indicative ·
52 / 100
View asset →
Estrogen Receptor Positive TumorDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →